Overview

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

Status:
Completed
Trial end date:
2014-09-23
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of cyclosporine 0.05% ophthalmic emulsion (Restasis®) in patients with dry eye disease.
Phase:
Phase 4
Details
Lead Sponsor:
Allergan
Treatments:
Carboxymethylcellulose Sodium
Cyclosporine
Cyclosporins
Lubricant Eye Drops
Ophthalmic Solutions
Tetrahydrozoline